JP2018111652A - Skin inflammation depressant, application implement - Google Patents

Abstract

PROBLEM TO BE SOLVED: To provide a skin inflammation depressant having an excellent inflammation depressant effect and improved usability, and an application implement.SOLUTION: The skin inflammation depressant is composed of an aqueous solution that contains benzalkonium chloride, and one selected from the group consisting of dibucaine hydrochloride and lidocaine hydrochloride. An application implement 10 for applying the skin inflammation depressant comprises a containing part 12 for containing the skin inflammation depressant, and an application core part 13 for exuding the skin inflammation depressant in the containing part 12. The application core part 13 is coupled to the containing part 12.SELECTED DRAWING: Figure 1

Description

  The present invention relates to an inflammation inhibitor for skin for suppressing inflammation caused on the skin such as acne and pimples, and an application device for applying the inflammation inhibitor for skin.

Conventionally, an antibacterial agent for suppressing the growth of skin resident bacteria such as acne bacteria that cause inflammation as a drug or composition such as an inflammation inhibitor for skin having an effect on skin inflammation such as acne The thing containing an agent and a disinfectant is proposed (for example, refer to the following patent documents 1-patent documents 8).
Patent Document 1 discloses a skin external preparation containing a predetermined amount of phospholipid and glycol ether, respectively, and having remarkably improved transdermal absorbability. The external preparation for skin can be combined with a local anesthetic, antipruritic agent, antibacterial agent and the like.
Patent Document 2 discloses a patch containing a water-sensitive polymer having bioadhesive properties, a water-soluble oligomer, a surfactant, and a medicinal component. The patch can use a local anesthetic as the medicinal component.
Patent Document 3 discloses an anhydrous topical composition containing a viscosity increasing agent, an organic solvent, and a humectant. A local anesthetic can be added to the anhydrous topical composition.
Patent Document 4 discloses an anti-acne vulgaris external preparation containing salicylic acid and a cationic surfactant. A bactericidal agent and a local anesthetic can be added to the anti-acne vulgaris external preparation.
Patent Document 5 discloses a skin ointment that uses oil, fat, silicone, and a gelling agent. Bactericides and local anesthetics can be added to the skin ointment.
Patent Document 6 discloses a sebum remover composition for acne and the like containing an inorganic salt, a nonionic surfactant, and a cationic surfactant. A local anesthetic can be added to the sebum remover composition.
Patent Document 7 includes (A) at least one selected from sodium chloride, magnesium chloride, magnesium sulfate, calcium chloride, potassium chloride, sodium bicarbonate, sodium carbonate, and (B) at least one selected from polyhydric alcohols. A topical pharmaceutical composition containing a seed is disclosed. A bactericidal agent and a local anesthetic can be added to the external pharmaceutical composition for skin.
In Patent Document 8, an anti-acne bacterium active component is supported on at least one of the inside or the surface of a biocompatible nanoparticle formed of either polylactic acid, polyglycolic acid, or a lactic acid / glycolic acid copolymer. An external preparation for skin is disclosed in which nanoparticles containing anti-acne bacteria active ingredients are dispersed in a powder, gel, solid substrate or liquid.

JP 2006-213695 A JP-T-2006-519263 Special table 2014-518282 gazette Japanese Patent Laid-Open No. 10-087496 JP-A-63-216817 JP 2000-191514 A JP 2001-187741 A Japanese Unexamined Patent Publication No. 2015-066752

However, conventional drugs and compositions such as skin inflammation inhibitors have been improved by adding a wide variety of active ingredients in addition to the main component, but this is still not sufficient and is not sufficient. The current situation is that improvement is required.
In particular, since conventional drugs and compositions are intended for the healing and complete cure after inflammation has occurred in the skin, that is, when the symptoms have progressed or worsened, a wide variety of active ingredients in addition to the main components Adds a strong medicinal effect. However, conventional drugs and compositions are used at the stage of signs that inflammation is likely to begin to appear, that is, in the state that can be dealt with and treated with self-healing power without borrowing the power of the drugs and compositions In order to do so, its strong medicinal properties are anxious. Therefore, from the viewpoint of health self-help that can be cured with self-healing power as much as possible without relying on strong medicinal effects, conventional drugs and compositions are still not sufficient, and inflammation can be controlled safely at the time of signs. An easy-to-use skin inflammation inhibitor is desired.
This invention is made | formed in view of the said situation, and is providing the inflammation inhibitor for skin and the applicator which are excellent in the inflammation suppression effect, and are easy to use.

In order to achieve the above object, an invention for an inflammation inhibitor for skin according to claim 1 comprises an aqueous solution containing benzalkonium chloride and at least one selected from dibucaine hydrochloride and lidocaine hydrochloride. It becomes the summary.
Invention of Claim 2 makes it a summary to contain the chlorpheniramine in the invention of the inflammation inhibitor for skin of Claim 1 further.
The gist of the invention described in claim 3 is that, in the skin inflammation inhibitor of the invention described in claim 1 or 2, water is 95% by mass or more.
The invention according to claim 4 is characterized in that in the invention for skin inflammation inhibitor according to any one of claims 1 to 3, the viscosity at 20 ° C. is 0.6 to 1.5 cP. .
The invention of the applicator according to claim 5 is a container that contains the skin inflammation inhibitor according to any one of claims 1 to 4 and an application that exudes the skin inflammation inhibitor in the container. A gist is provided with a core part, and the application core part is connected with the storage part.
The gist of the invention according to claim 6 is that, in the invention of the applicator according to claim 5, a piston for pressing the skin inflammation inhibitor is provided in the housing portion.

[Action]
The skin inflammation inhibitor of the present invention comprises an aqueous solution containing benzalkonium chloride and at least one selected from dibucaine hydrochloride and lidocaine hydrochloride.
In the inflammation inhibitor for skin, the benzalkonium chloride, which is a bactericidal component, suppresses the inhabitation of skin resident bacteria that cause skin inflammation, thereby preventing the progression and deterioration of inflammation at the sign stage. Suppresses the inflammation so that it can self-heal.
On the other hand, although the inflammation has been stopped in a state where self-healing is possible, the skin irritation site is weak and a peculiar sense of incongruity remains. Inflammation may be exacerbated by secondary infection. Therefore, the dibucaine hydrochloride and / or lidocaine hydrochloride, which is an anesthetic component, reduces the sense of the applied site and makes the presence of inflammation disappear, so that secondary inflammation can be achieved by touching the inflammation with a dirty finger. Reduces infection and discomfort.
Further, since the skin inflammation inhibitor is an aqueous solution, it is difficult to be absorbed into the body from the skin surface (hereinafter also referred to as “transdermal absorption”), and the benzalkonium chloride, which is a bactericidal component, is removed from the skin surface. Therefore, the benzalkonium chloride can be preferably caused to act on skin resident bacteria that cause inflammation that inhabit the skin surface and pores.
And, the skin inflammation inhibitor can sufficiently cope with and treat the signs of inflammation with self-healing power by using the benzalkonium chloride and dibucaine hydrochloride and / or lidocaine hydrochloride. Because it can be maintained in an almost aseptic and sensory state for a certain period of time, it has excellent anti-inflammatory effects and is easy to use from the viewpoint of health self-help that can be cured with self-healing power as much as possible without relying on strong medicinal effects. (Claim 1).
Moreover, the said skin inflammation inhibitor can suppress the redness of skin by containing the chlorpheniramine which is an antihistamine component further (Claim 2).
Moreover, the said inflammation inhibitor for skin can be set to have almost no influence on skin by making water 95 mass% or more (Claim 3).
The skin inflammation inhibitor has a very low viscosity of 0.6 to 1.5 cP at 20 ° C., so that the skin inflammation inhibitor stays on the skin for a long time. The percutaneous absorption of benzalkonium can be suppressed and the usability can be improved (claim 4).
The applicator of the present invention includes a housing portion that houses the skin inflammation inhibitor and a coating core portion that exudes the skin inflammation inhibitor in the housing portion, and the coating core portion is connected to the housing portion. It has a simple configuration. Then, the applicator can easily apply an appropriate amount of the inflammation inhibitor for skin to the location without limitation of place and time, for example, by pressing the coating core against the location where the signs of inflammation are felt. Therefore, it can be made easy to use from the viewpoint of health self-help (claim 5).
In addition, since the application device is provided with a piston in the housing portion, even when the skin inflammation inhibitor in the container body decreases due to use, the piston presses the skin inflammation inhibitor with the piston. By doing so, the inflammation inhibitor for skin can be used without waste (Claim 6).

[effect]
ADVANTAGE OF THE INVENTION According to this invention, it is excellent in the inflammation suppression effect and can provide the user-friendly skin inflammation inhibitor and applicator.

(A), (b) is sectional drawing which shows the applicator of embodiment. The photograph which shows the observation result of Example 2.

Hereinafter, an embodiment embodying the present invention will be described.
The inflammation inhibitor for skin of this invention consists of an aqueous solution containing benzalkonium chloride and one selected from the group consisting of dibucaine hydrochloride and lidocaine hydrochloride.

The benzalkonium chloride is a bactericidal component. That is, the benzalkonium chloride suppresses the presence of skin resident bacteria that cause skin inflammation, particularly acne bacteria that cause acne (propionibacterium acnes), and more specifically, the inflammation stage. It suppresses the progression and worsening of inflammation.
In the skin inflammation inhibitor, the amount of the benzalkonium chloride added is preferably 0.01 to 0.5% by mass, more preferably 0.01 to 0.2% by mass, and still more preferably 0.05 to 0.2% by mass. When the addition amount of the sterilizing component is excessively small, the sterilizing effect cannot be obtained, and when it is excessively large, not only a sufficient effect cannot be obtained, but there is a possibility that the skin is damaged.

The dibucaine hydrochloride and the lidocaine hydrochloride are anesthetic components. That is, the dibucaine hydrochloride or the lidocaine hydrochloride suppresses the deterioration of the inflammation by dulling the sense of the applied site when the skin inflammation inhibitor is applied to the skin.
More specifically, the benzalkonium chloride is more than sufficient to suppress the inhabitation of skin resident bacteria that cause inflammation, particularly acne bacteria, in order to make the environment capable of coping and treating the inflammation by self-healing power. It is a bactericidal component having the following performance. However, when the skin inflammation inhibitor is applied to the skin, the treatment and treatment by self-healing power has not yet progressed, and the skin is weak, so that the skin is swollen as an uncomfortable feeling peculiar to inflammation. Pain and irritation / itchiness remain. The user is worried about the sense of incongruity, and touches the applied part with his / her finger, but when this happens, the bacteria attached to the dirty finger are secondary infected to the weakened skin, Causes inflammation, especially acne. The dibucaine hydrochloride and the lidocaine hydrochloride, by the anesthetic action, dull the sensation of the applied site to eliminate the uncomfortable feeling peculiar to inflammation and make the presence of the inflammation not felt by the user. By suppressing the touching of the place with a finger and maintaining an environment in which the inflammation can be treated and treated by the self-healing power, the progression and deterioration of the inflammation are prevented.
In the present invention, dibucaine hydrochloride and / or lidocaine hydrochloride are used as an anesthetic component, but these may be used in combination or may be used alone. The content of the anesthetic component is described below, but this content is common when used in combination or when used alone.
In the skin inflammation inhibitor, the amount of dibucaine hydrochloride or lidocaine hydrochloride added is preferably 0.05 to 0.5% by mass, more preferably 0.1% to 0.2% by mass, and still more preferably. It is 0.2-0.5 mass%. If the amount of the anesthetic component added is too small, the effect of anesthesia will not be obtained, and if it is excessively large, the feeling of dullness may be a concern, and the applied part may be touched with fingers. Get higher.
In addition, the dibucaine hydrochloride and the lidocaine hydrochloride are amide type local anesthetics, and have a property that tissue permeability and stability are high and allergic reaction is small. In addition, when the dibucaine hydrochloride and the lidocaine hydrochloride are compared, the dibucaine hydrochloride has higher efficacy and the anesthetic effect can be obtained even in a smaller amount. It is more preferable to use
In addition, the dibucaine hydrochloride and the lidocaine hydrochloride are used together with an appropriate amount of a pH adjusting agent because the anesthetic action is accelerated as the acid dissociation constant (pKa) is closer to the intracellular pH of 7.4. You can also.

The inflammatory inhibitor for skin of the present invention may further contain chlorpheniramine. This chlorpheniramine is an antihistamine component. That is, in the case of inflammation of the skin, particularly acne, redness may occur in the skin as a discomfort peculiar to inflammation due to histamine generated by an antigen-antibody reaction. The chlorpheniramine suppresses the redness of the skin by suppressing the action of the histamine.
In the skin inflammation inhibitor, the amount of the chlorpheniramine added is preferably 0.03 to 0.07% by mass, more preferably 0.03 to 0.06% by mass, and still more preferably 0.04 to 0%. 0.06% by mass. When the addition amount of the antihistamine component is excessively small, the effect of suppressing the action of histamine cannot be obtained, and when it is excessively large, side effects due to the antihistamine component may occur.

In the skin inflammation inhibitor, water such as purified water or alkaline ionized water is used as a solvent for each component. That is, since the skin inflammation inhibitor is an aqueous solution using water as a solvent, the percutaneous absorption is suppressed, so that the benzalkonium chloride, which is a bactericidal component, is not absorbed through the skin. It is possible to sterilize skin resident bacteria that cause inflammation such as acne bacteria in the skin surface and pores.
The ratio of the water in the skin inflammation inhibitor is preferably 95% by mass or more, more preferably 97% by mass or more, still more preferably 97% by mass or more and less than 100% by mass. That is, most of the components of the skin inflammation inhibitor are water, and are excellent in safety.

The skin inflammation inhibitor preferably has a viscosity at 20 ° C. of 0.6 to 1.5 cP from the viewpoint of low viscosity. If the viscosity is excessively low, the skin inflammation inhibitor cannot remain at the site of skin inflammation and flows down. If the viscosity is excessively high, the skin inflammation inhibitor is prolonged on the skin. By staying for a period of time, the sterilizing component may be absorbed through the skin, and the skin may be damaged.
In addition, when the skin inflammation inhibitor is applied to the skin, it can be applied to the skin by soaking it in a porous material such as felt or sponge, or a water absorbent material such as absorbent cotton, cosmetic puff or gauze. , It improves usability. And in order to make the said porous body and the said water absorbing body penetrate | infiltrate the said inflammation inhibitor for skin suitably, it is preferable to make the said inflammation inhibitor for skin low viscosity.

In addition to the above bactericidal component, anesthetic component, and antihistamine component, the skin inflammation inhibitor includes alcohols such as ethanol, viscosity modifiers, and stabilizers as long as the effects of the present invention are not impaired as desired. , Preservatives, antioxidants, fragrances and the like can be included.
However, when other components such as alcohols and fragrances are added, the selection of the active ingredients and the adjustment of the addition amount become complicated and the composition becomes complicated. Further, it is desired that the skin inflammation inhibitor is not applied to the skin. In particular, from the viewpoint that it is applied to the face if it is acne, it is desired not to contain an excessive additive. As the extra additive, for example, a silicone-based additive has a high possibility of leaving a trace such as a stain by giving an extra burden on the skin, and is particularly undesirable as an additive for the inflammation inhibitor for the skin. It is.
Therefore, the skin inflammation inhibitor contains only two components, a bactericidal component and an anesthetic component (including a pH adjuster), or only three components including an antihistamine component as required. It is desirable not to contain such additives.

The above-mentioned skin inflammation inhibitor is used by applying it to a site having a peculiar discomfort with respect to inflammation such as acne, that is, a site having signs of inflammation such as swelling / pain or redness of the skin. The skin inflammation inhibitor contains the benzalkonium chloride, which is a bactericidal component, and dibucaine hydrochloride and / or lidocaine, which is an anesthetic component, and is capable of self-healing where there is an indication of inflammation. Maintain an almost aseptic and numb state for a predetermined amount of time that is sufficient for coping and treatment. That is, the skin inflammation inhibitor prepares an environment for healing with its own healing power by the necessary and sufficient bactericidal ability of the benzalkonium chloride at an early stage against inflammation such as acne, and the dibucaine By maintaining the environment by the anesthetic ability of hydrochloride or lidocaine hydrochloride, the composition is kept only necessary and sufficient, and it has an excellent anti-inflammatory effect in terms of self-help that can be cured with its own healing power as much as possible. It is easy to use.
Moreover, the inflammation inhibitor for skin of this invention can be used suitably as an acne treatment agent. And as above-mentioned, since it can be set as the low-viscosity aqueous solution about 1.0 to 1.2 times the viscosity of water, the touching feeling to skin is as good as water. Furthermore, the present invention can be made into a transparent aqueous solution, and when applied to the skin, the skin inflammation inhibitor does not stand out and is excellent in appearance.

An applicator for applying the skin inflammation inhibitor will be described.
As shown in FIG. 1A, a main body case 11 of the applicator 10 includes a cylindrical body 11A having a base end (right end in the figure) and a distal end (left end in the figure) opened, and a base of the cylinder 11A. It is comprised by the cover body 11B which block | closes opening of an end.
An accommodating portion 12 for accommodating the skin inflammation inhibitor is provided inside the cylindrical body 11A. Further, the cylindrical body 11A has a shape in which the diameter of the end portion on the distal end side is reduced toward the distal end. Therefore, the opening at the distal end of the cylindrical body 11A is compared with the opening at the proximal end. The diameter is narrowed. And the application | coating core part 13 is inserted by opening at the front-end | tip of the said cylinder 11A.

The material of the coating core 13 is not particularly limited, but it is preferable to use a material made of a porous material from the viewpoint that the skin inflammation inhibitor is likely to permeate and exude easily. Examples of the porous material include fiber materials made of natural fibers such as knitted fabrics, woven fabrics, and nonwoven fabrics, synthetic fibers and semi-synthetic fibers, and open cells made of synthetic resin, foams such as sponges made of natural materials, and the like.
The coating core part 13 is connected to the housing part 12. The connection between the coating core portion 13 and the housing portion 12 may be penetration or insertion of the coating core portion 13 into the housing portion 12. That is, it is only necessary that the skin inflammation inhibitor in the container 12 is installed (joined) so as to contact the coating core 13. The skin inflammation inhibitor in the container 12 is in contact with the coating core 13 and soaks into the entire coating core 13 by capillary action. In the coating core 13, the skin inflammation is inflamed. Inhibitors are exuded.

Further, the shape of the coating core portion 13 is not particularly limited. It can be in the shape of a rod or spatula such as a cylindrical column or a polygonal column such as a quadrangular column, or a combination of these structures.
Further, as shown in FIG. 1, the coating core portion 13 can be a coating core body 13A made of a porous material or the like and a relay core 13B made of a thin tube. In this case, the coating core body 13A is connected to the housing portion 12 via a relay core 13B made of a thin tube. The relay core 13 </ b> B has a base end that reaches the inside of the housing portion 12, and is in contact with the skin inflammation inhibitor in the housing portion 12.
In addition, the applicator 10 includes a cap 14 that can be attached to and detached from the main body case 11. The cap 14 has a cylindrical shape with a closed end, and is configured to be attached to the main body case 11 by inserting the front end portion of the main body case 11 therein. The cap 14 is attached to the main body case 11 to cover the coating core 13 and the like from the outside, thereby protecting the coating core 13 from dirt and dryness, and suppressing the inflammation for the skin. Prevents the agent from adhering to undesired locations of the user.

In the applicator 10, the skin inflammation inhibitor is accommodated in the accommodating portion 12 in a liquid state, for example, by removing the lid 11B of the main body case 11. The inflammation inhibitor for skin housed in the housing portion 12 is sent to the coating core body 13A via the relay core 13B by capillary action and soaks into the entire coating core body 13A. It reaches the tip of the coating core body 13A. When the applicator 10 is used, the cap 14 is removed from the main body case 11, and the tip of the application core part 13 is pressed against an affected part such as acne, so that the skin oozes from the application core part 13. An appropriate amount of anti-inflammatory agent is applied to the affected area.
The applicator device 10 applies the skin inflammation inhibitor to the inflammation when the user notices a peculiar discomfort when acne occurs, for example, signs of inflammation such as swelling / pain or skin redness. It is intended to be able to be applied to places where there is a sign of, without worrying about place or time. Therefore, the applicator 10 has an excellent anti-inflammatory effect from the viewpoint of self-help that can be cured with self-healing power as much as possible by suppressing inflammation at the sign stage, and is easy to use.
As described above, since the skin inflammation inhibitor is a low viscosity having a viscosity of 0.6 to 1.5 cP at 20 ° C., the capillary phenomenon is likely to occur, and the penetration into the coating core 13 is further caused. The exudation from the coating core 13 is performed extremely well.
The skin inflammation inhibitor is not limited to being housed in the housing portion 12 in a liquid state, but is soaked in a batting material made of a porous material such as a cotton-like material or a sponge material. In a state, it may be accommodated in the accommodating portion 12. When the skin inflammation inhibitor is soaked into the batting material and accommodated in the accommodating portion 12, the relay core 13B is omitted, and the base end portion of the coating core main body 13A is disposed in the accommodating portion 12. The application core portion 13 and the housing portion 12 are directly connected to each other, and the proximal end portion of the application core portion 13 is in contact with the batting material soaked with the skin inflammation inhibitor. Configure.

Furthermore, as shown in FIG.1 (b), the said application device 10 can also provide the piston 15 in the said accommodating part 12 so that a movement is possible.
That is, the piston 15 is inserted into the housing portion 12. A convex portion 15 </ b> A is provided on the circumferential surface of the piston 15. A concave strip 11C is provided on the inner peripheral surface of the accommodating portion 12 so as to extend in the axial direction of the cylindrical body 11A. The piston 15 inserted in the housing portion 12 is restricted from rotating around the axis of the cylindrical body 11A by the engagement of the convex portion 15A and the concave strip 11C. It is comprised so that the inside of the said accommodating part 12 can be moved along the axis line of 11A.

In addition, the applicator 10 has a mechanism that allows the piston 15 to move as desired by the user. The mechanism includes a knob 16 provided outside the lid body 11B of the main body case 11, and a shaft body 17 extending from the center of the front end surface of the knob 16 in the axial direction of the cylindrical body 11A.
The knob 16 is configured to be rotatable around the shaft body 17 outside the lid body 11B by inserting the shaft body 17 through a through hole 11D formed at the center of the lid body 11B. Yes.
The shaft body 17 is restricted from slipping out of the through hole 11D of the lid body 11B by a retaining member 17A provided at the base end thereof. A male thread groove is threaded on the peripheral surface of the shaft body 17. A female screw hole 15B is formed through the center of the piston 15, and the piston 15 is screwed to the shaft body 17 through the female screw hole 15B.

In the mechanism, when the knob 16 is rotated in a predetermined direction, the shaft body 17 rotates with the rotation. Since the piston 15 is restricted from rotating about the axis of the cylinder 11A and is screwed with the shaft body 17, the shaft 17 is rotated from the female screw hole 15B when the shaft body 17 rotates. The body 17 is screwed out and moves in the accommodating portion 12 in the distal direction along the axis of the cylindrical body 11A as indicated by a two-dot chain line in FIG.
The piston 15 and the mechanism are useful for using the skin inflammation inhibitor in the applicator 10 without waste. That is, when the remaining amount of the skin inflammation inhibitor in the housing portion 12 decreases, the mechanism moves the piston 15 toward the distal end in the housing portion 12 to move the housing portion 12. It becomes possible to press the skin inflammation-suppressing agent contained in the skin and push it toward the coating core 13.
Note that the piston 15 is not necessarily moved using the mechanism, and a rod or the like is inserted into the through hole 11D using, for example, a through hole 11D formed at the center of the lid 11B. The piston 15 may be moved by, for example.

  Examples of the present invention will be described below, but the present invention is not limited to these examples. In the following, “part” and “%” are based on mass unless otherwise specified.

[Preparation of skin inflammation inhibitor]
Example 1
To 100 parts of water, 0.2 part of benzalkonium chloride, 0.5 part of dibucaine hydrochloride, and 0.05 part of chlorpheniramine were added to obtain a sample. The concentration and viscosity of each component were as follows.
Water: 99.99295%
Benzalkonium chloride: 0.2%
Dibucaine hydrochloride: 0.5%
Chlorpheniramine: 0.05%
Viscosity (20 ° C.): 1.00 cP

(Example 2)
A sample was obtained by adding 0.2 part of benzalkonium chloride and 0.5 part of dibucaine hydrochloride to 100 parts of water. The concentration and viscosity of each text were as follows.
Water: 99.993%
Benzalkonium chloride: 0.2%
Dibucaine hydrochloride: 0.5%
Viscosity (20 ° C.): 1.00 cP

(Comparative Example 1)
A sample was obtained by adding 0.2 parts of benzalkonium chloride to 100 parts of water. The concentration and viscosity of each text were as follows.
Water: 99.998%
Benzalkonium chloride: 0.2%
Viscosity (20 ° C.): 1.00 cP

〔Effect confirmation〕
For each of the samples of Examples 1 and 2 and Comparative Example 1, an appropriate amount was applied to the acne for the first group and second group investigators, 3 minutes, 1 hour, 12 hours after application, The presence or absence of discomfort was evaluated.
In the first group, one person under 25 years of age and one person who had an elapsed time of 5 hours or less after the occurrence of acne were 1 person in total.
In the second group, one person who was over 30 years old and one person who had passed 12 hours after acne occurred were a total of two persons.
Regarding the presence / absence of discomfort, A: presence / absence of irritation by application, B: presence / absence of swelling / pain due to acne, C: presence / absence of redness of skin due to acne, ◎ In the case of people, Δ, and in the case of two people, ×.
The results are shown in Table 1.

From the results of Table 1, there was no person who evaluated that A: presence or absence of stimulation by application was in both the first and second groups. For this reason, it was shown that benzalkonium chloride, which is a bactericidal component, kills the causative bacteria in about 3 minutes.
B: No one evaluated the presence or absence of swelling / pain due to acne in the first group. In the second group, there was a person who evaluated that it was Comparative Example 1 until one hour later. For this reason, it was shown that dibucaine hydrochloride, which is an anesthetic component, suitably suppresses swelling and pain. In addition, as a result of comparing the first group and the second group, the skin inflammation suppressant is said to be healthy self-help that heals as much as possible with its own healing power by suppressing inflammation at an early stage, that is, at an early stage. From the viewpoint, it was shown to be excellent. Furthermore, in the second group, nobody evaluated that there was swelling / pain after 12 hours, and the skin inflammation inhibitor maintained the place where acne occurred for about 1 hour. It was shown that treatment with healing power is possible.
C: None of the first and second groups evaluated the presence or absence of skin redness due to acne as being in Example 1. In Example 2 and Comparative Example 1, there was a person who evaluated that there was until 1 hour later. As for Example 2, as shown in FIG. 2, when comparing before application (before column in the figure) and after application (after field in the figure), the first group (1 column in the figure) Then, redness remained after application for some of the acne that had progressed, and redness remained after application for all of the acne that had progressed in the second group (column 2 in the figure). For this reason, chlorpheniramine which is an antihistamine component was shown to suppress the redness of the skin suitably.

  According to the present invention, the skin inflammation inhibitor and the applicator can be made inexpensive and easy to use, and thus are industrially applicable.

DESCRIPTION OF SYMBOLS 10 Application | coating instrument 11 Main body case 11A Tubular body 11B Lid body 11C Concave strip 11D Through-hole 12 Storage part 13 Application | coating core part 13A Application | coating core main body 13B Relay core 14 Cap 15 Piston 15A Convex part 15B Female screw hole 16 Knob 17 Shaft body 17A Exit Stop

Claims (6)

  An inflammation inhibitor for skin, comprising an aqueous solution containing benzalkonium chloride and at least one selected from dibucaine hydrochloride and lidocaine hydrochloride.   Furthermore, the inflammation inhibitor for skin of Claim 1 containing a chlorpheniramine.   The skin inflammation inhibitor according to claim 1 or 2, wherein water is 95% by mass or more.   The inflammation inhibitor for skin according to any one of claims 1 to 3, wherein the viscosity at 20 ° C is 0.6 to 1.5 cP. A container that houses the skin inflammation inhibitor according to any one of claims 1 to 4, and a coating core that exudes the skin inflammation inhibitor in the container,
The applicator device, wherein the applicator core part is connected to the housing part. The applicator according to claim 5, wherein a piston that presses the skin inflammation inhibitor is provided in the housing portion.

Images